MMGH Consulting GmbH, Zurich, Switzerland.
Gavi, The Vaccine Alliance, Geneva, Switzerland.
Front Public Health. 2023 Jun 12;11:1165110. doi: 10.3389/fpubh.2023.1165110. eCollection 2023.
Innovative vaccine products will be critical in helping to address the existing implementation barriers that have prevented the achievement of the measles and rubella (MR) vaccine coverage targets. Overcoming those barriers will be necessary to achieve the "Immunization Agenda 2030" goals. Microarray patches (MAPs), an innovative needle-free delivery device currently in clinical development, can be a potential game changer in this respect and contribute to the equitable delivery of vaccines in low- and middle-income countries and pandemic preparedness and response. Developing in-depth knowledge of the most desired and impactful uses of MRMAPs can prove critical to identifying the critical attributes of the target product profile, informing policy and adoption decisions, and helping to evaluate the potential public health and economic value of this technology. The first step in this process is the definition of the potential use cases for MR-MAPs, i.e., where and how this product is most likely to be used within the immunization programme.
By applying a design-based user-centric approach, we implemented a three-step process, including a desk review, a survey, and interviews, to define the most relevant use cases for MR MAPS.
Six use cases have been identified as relevant across all different countries and immunization programme designs and validated by experts.
The identified use cases have already informed the demand estimate for MR-MAPs and provided the foundation for developing an initial full vaccine value assessment. We believe that, in the future, they will be highly valuable in ensuring that the roll-out of this promising innovation is designed in a way that maximizes the impact, particularly in populations and countries that are most in need.
创新疫苗产品对于克服现有实施障碍，实现麻疹和风疹（MR）疫苗覆盖率目标至关重要。克服这些障碍对于实现“免疫议程 2030”目标是必要的。微阵列贴片（MAP）是一种创新的无针输送装置，目前正在临床开发中，在这方面可能具有改变游戏规则的潜力，并有助于在中低收入国家公平提供疫苗以及为大流行的预防和应对提供支持。深入了解最需要和最有影响力的 MRMAP 用途可能对于确定目标产品概况的关键属性、为政策和采用决策提供信息以及帮助评估这项技术的潜在公共卫生和经济效益至关重要。这一过程的第一步是定义 MR-MAP 的潜在用例，即该产品最有可能在免疫规划中何处以及如何使用。
通过应用基于设计的以用户为中心的方法，我们实施了一个三步流程，包括桌面审查、调查和访谈，以确定 MR MAP 的最相关用例。
已经确定了六个与所有不同国家和免疫规划设计相关的用例，并得到了专家的验证。
确定的用例已经为 MR-MAP 的需求估计提供了信息，并为初步的全面疫苗价值评估奠定了基础。我们相信，在未来，它们将非常有价值，确保这项有前途的创新的推出方式能够最大限度地发挥影响力，特别是在最需要的人群和国家。
